Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis.
暂无分享,去创建一个
Yongfeng Zhao | D. Sultan | Yongjian Liu | L. Detering | H. Luehmann | D. Abdalla | S. Kazuma | Meng You | Deborah Sultan
[1] M. Tian. Molecular Imaging of Small Animals: Instrumentation and Applications , 2015, The Journal of Nuclear Medicine.
[2] U. Haberkorn,et al. Radionuclides in drug development. , 2015, Drug discovery today.
[3] P. Lambin,et al. Reversal of Hypoxia in Murine Atherosclerosis Prevents Necrotic Core Expansion by Enhancing Efferocytosis , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[4] Jason S. Lewis,et al. Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET , 2014, The Journal of Nuclear Medicine.
[5] Forrest M Kievit,et al. Glypican-3–Targeting F(ab′)2 for 89Zr PET of Hepatocellular Carcinoma , 2014, The Journal of Nuclear Medicine.
[6] René M. Botnar,et al. PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc). , 2014, International journal of cardiology.
[7] Yongjian Liu,et al. Facile synthesis, pharmacokinetic and systemic clearance evaluation, and positron emission tomography cancer imaging of ⁶⁴Cu-Au alloy nanoclusters. , 2014, Nanoscale.
[8] R. Tavaré,et al. Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer , 2014, Clinical Cancer Research.
[9] Jaw-Yuan Wang,et al. PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy , 2014, Molecular Cancer Therapeutics.
[10] Gilles Barone-Rochette,et al. 99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice , 2014, The Journal of Nuclear Medicine.
[11] M. Frómeta,et al. Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody , 2014, mAbs.
[12] B. Cosyns,et al. Recent Advances in Visualizing Vulnerable Plaque: Focus on Noninvasive Molecular Imaging , 2014, Current Cardiology Reports.
[13] C. Stefanadis,et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. , 2014, Journal of the American College of Cardiology.
[14] Bernadette V. Marquez,et al. Glypican-3–Targeted 89Zr PET Imaging of Hepatocellular Carcinoma: Where Antibody Imaging Dares to Tread , 2014, The Journal of Nuclear Medicine.
[15] Eric D. Pressly,et al. PET/CT Imaging of Chemokine Receptor CCR5 in Vascular Injury Model Using Targeted Nanoparticle , 2014, The Journal of Nuclear Medicine.
[16] E. Garcı́a-España,et al. Visualizing the atherosclerotic plaque: a chemical perspective. , 2014, Chemical Society reviews.
[17] G. Coukos,et al. Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin , 2014, The Journal of Nuclear Medicine.
[18] V. Fuster,et al. Noninvasive Assessment of Hypoxia in Rabbit Advanced Atherosclerosis Using 18F-fluoromisonidazole Positron Emission Tomographic Imaging , 2014, Circulation. Cardiovascular imaging.
[19] Adriano G. Rossi,et al. Apoptotic cell clearance: basic biology and therapeutic potential , 2014, Nature Reviews Immunology.
[20] E. Ruoslahti,et al. 64Cu-Labeled LyP-1-Dendrimer for PET-CT Imaging of Atherosclerotic Plaque , 2014, Bioconjugate chemistry.
[21] Mikako Ogawa,et al. Development of 111In-Labeled Liposomes for Vulnerable Atherosclerotic Plaque Imaging , 2014, The Journal of Nuclear Medicine.
[22] A. Zernecke,et al. Molecular Imaging of Inflammation in Atherosclerosis , 2013, Theranostics.
[23] M. Daemen,et al. Evaluation of 111In-labeled EPep and FibPep as tracers for fibrin SPECT imaging. , 2013, Molecular pharmaceutics.
[24] M. Daemen,et al. Hypoxia in atherosclerosis and inflammation , 2013, Current opinion in lipidology.
[25] D. Teupser,et al. Altered Expression of Raet1e, a Major Histocompatibility Complex Class 1–Like Molecule, Underlies the Atherosclerosis Modifier Locus Ath11 10b , 2013, Circulation research.
[26] J. S. Lee,et al. Feasibility and kinetic characteristics of 68Ga-NOTA-RGD PET for in vivo atherosclerosis imaging , 2013, Annals of Nuclear Medicine.
[27] P. Perret,et al. In Vivo Molecular Imaging of Atherosclerotic Lesions in ApoE-/-mice using VCAM-1-Specific , 99 m Tc-Labeled Peptidic Sequences , 2013 .
[28] R. Pierce,et al. PET Imaging of Chemokine Receptors in Vascular Injury–Accelerated Atherosclerosis , 2013, The Journal of Nuclear Medicine.
[29] F. Mach,et al. The vulnerable coronary plaque: update on imaging technologies , 2013, Thrombosis and Haemostasis.
[30] P. Libby,et al. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. , 2013, Immunity.
[31] Yasuyoshi Watanabe,et al. Novel molecular imaging of atherosclerosis with gallium-68-labeled apolipoprotein A-I mimetic peptide and positron emission tomography. , 2013, Circulation journal : official journal of the Japanese Circulation Society.
[32] Daniel G. Anderson,et al. Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in Atherosclerosis-Prone Mice , 2013, Circulation.
[33] Yasuyoshi Watanabe,et al. Detection of early stage atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density lipoprotein receptor-deficient mice. , 2013, Biochemical and biophysical research communications.
[34] Ralph Weissleder,et al. Polymeric Nanoparticle PET/MR Imaging Allows Macrophage Detection in Atherosclerotic Plaques , 2013, Circulation research.
[35] Linda A. Jelicks,et al. MicroPET/SPECT/CT imaging of small animal models of disease. , 2013, The American journal of pathology.
[36] P. Libby,et al. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. , 2012, Circulation research.
[37] Hua-Lin Wu,et al. In vivo examination of 111In-bis-5HT-DTPA to target myeloperoxidase in atherosclerotic ApoE knockout mice , 2012, Journal of drug targeting.
[38] A. Walch,et al. Diet intervention reduces uptake of αvβ3 integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques , 2012, Journal of Nuclear Cardiology.
[39] Jakub Toczek,et al. Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.
[40] A. Sinusas,et al. Atherosclerosis Plaque Heterogeneity and Response to Therapy Detected by In Vivo Molecular Imaging of Matrix Metalloproteinase Activation , 2011, The Journal of Nuclear Medicine.
[41] J. Knuuti,et al. Uptake of 68gallium in atherosclerotic plaques in LDLR-/-ApoB100/100 mice , 2011, EJNMMI research.
[42] J. Correia,et al. Radiometallated peptides for molecular imaging and targeted therapy. , 2011, Dalton transactions.
[43] Jean-Claude Tardif,et al. Imaging Biomarkers in Atherosclerosis Trials , 2011, Circulation. Cardiovascular imaging.
[44] J. Knuuti,et al. Detection of Hypoxia by [18F]EF5 in Atherosclerotic Plaques in Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[45] I. Y. Chen,et al. Cardiovascular molecular imaging: focus on clinical translation. , 2011, Circulation.
[46] H. Saji,et al. Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[47] C. Meyer,et al. Molecular Imaging of Atherosclerotic Plaques Targeted to Oxidized LDL Receptor LOX-1 by SPECT/CT and Magnetic Resonance , 2010, Circulation. Cardiovascular imaging.
[48] P. Low,et al. Imaging of Atherosclerosis in Apoliprotein E Knockout Mice: Targeting of a Folate-Conjugated Radiopharmaceutical to Activated Macrophages , 2010, Journal of Nuclear Medicine.
[49] Ralph Weissleder,et al. The Vascular Biology of Atherosclerosis and Imaging Targets , 2010, Journal of Nuclear Medicine.
[50] K. Någren,et al. Uptake of 11C-Choline in Mouse Atherosclerotic Plaques , 2010, Journal of Nuclear Medicine.
[51] M. Welch,et al. Molecular Imaging of Atherosclerotic Plaque with 64Cu-Labeled Natriuretic Peptide and PET , 2010, Journal of Nuclear Medicine.
[52] Ralph Weissleder,et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. , 2009, JACC. Cardiovascular imaging.
[53] J. Knuuti,et al. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[54] A. Walch,et al. Evaluation of &agr;v&bgr;3 Integrin-Targeted Positron Emission Tomography Tracer 18F-Galacto-RGD for Imaging of Vascular Inflammation in Atherosclerotic Mice , 2009, Circulation. Cardiovascular imaging.
[55] N. Narula,et al. Molecular Imaging of Matrix Metalloproteinase Expression in Atherosclerotic Plaques of Mice Deficient in Apolipoprotein E or Low-Density-Lipoprotein Receptor , 2009, Journal of Nuclear Medicine.
[56] D. Kraitchman,et al. Advances in Cardiovascular Imaging Multimodality Cardiovascular Molecular Imaging, Part II , 2008 .
[57] A. Sinusas,et al. Molecular Imaging of Activated Matrix Metalloproteinases in Vascular Remodeling , 2008, Circulation.
[58] H. Saji,et al. Targeting of Lectinlike Oxidized Low-Density Lipoprotein Receptor 1 (LOX-1) with 99mTc-Labeled Anti–LOX-1 Antibody: Potential Agent for Imaging of Vulnerable Plaque , 2008, Journal of Nuclear Medicine.
[59] M. Bergström,et al. The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. , 2008, Nuclear medicine and biology.
[60] Ralph Weissleder,et al. Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.
[61] D. Boturyn,et al. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[62] A. Fischman,et al. Detection of inflamed atherosclerotic lesions with diadenosine-5′,5‴-P1,P4-tetraphosphate (Ap4A) and positron-emission tomography , 2006, Proceedings of the National Academy of Sciences.
[63] R. Virmani,et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[64] S. Cherry,et al. Physics in Nuclear Medicine , 2004 .
[65] H. Watabe,et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] Otmar Schober,et al. Scintigraphic Imaging of Matrix Metalloproteinase Activity in the Arterial Wall In Vivo , 2004, Circulation.
[67] R. Virmani,et al. Targeting of Apoptotic Macrophages and Experimental Atheroma With Radiolabeled Annexin V: A Technique With Potential for Noninvasive Imaging of Vulnerable Plaque , 2003, Circulation.
[68] J. Plutzky. The vascular biology of atherosclerosis. , 2003, The American journal of medicine.
[69] Christodoulos Stefanadis,et al. Vulnerable plaque: the challenge to identify and treat it. , 2003, Journal of interventional cardiology.
[70] J. Witztum,et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[71] G. Hansson,et al. Immune mechanisms in atherosclerosis. , 1994, Coronary artery disease.
[72] C. Zarins,et al. Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.
[73] J. Witztum,et al. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. , 1984, Journal of lipid research.
[74] Gopal B. Saha,et al. Fundamentals of Nuclear Pharmacy , 1979, Springer New York.
[75] E. Falk,et al. Mechanisms of Plaque Formation and Rupture , 2014 .
[76] Christoph Hoeschen,et al. Radiation physics for nuclear medicine , 2011 .
[77] A. Alwan. Global status report on noncommunicable diseases 2010. , 2011 .
[78] Andrew V. Sutherland,et al. Molecular tracers for the PET and SPECT imaging of disease. , 2011, Chemical Society reviews.
[79] John Andersson,et al. Adaptive immunity and atherosclerosis. , 2010, Clinical immunology.
[80] G. Hansson,et al. Innate immune signals in atherosclerosis. , 2010, Clinical immunology.
[81] K. Någren,et al. Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[82] Jason S. Lewis,et al. Molecular imaging: The application of small animal positron emission tomography , 2002, Journal of cellular biochemistry. Supplement.
[83] Samuel A Wickline,et al. Molecular imaging, targeted therapeutics, and nanoscience , 2002, Journal of cellular biochemistry. Supplement.
[84] Syed M. Qaim,et al. Nuclear data relevant to the production and application of diagnostic radionuclide , 2001 .
[85] J. Witztum,et al. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo , 1999, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.